By Connor Hart
Shares of Theratechnologies jumped after the company received Food and Drug Administration approval for Egrifta WR, its treatment for excess abdominal fat in adults with HIV and lipodystrophy.
The stock climbed 50%, to $2.32, in after-hours trading Tuesday. Shares are up 15% in the past year through the close, despite having fallen 16% in the past three months.
The Canadian biopharmaceutical company said the treatment is set to replace Egrifta SV. The new formulation is a daily injectable requiring weekly reconstitution, meaning it requires less than half the administration volume as the current formulation, which is reconstituted daily.
The treatment will be manufactured at a new U.S.-based contract drug manufacturing organization, and is set to be patent protected in the U.S. until 2033, the company said.
"We are pleased to offer this improved, more convenient version of tesamorelin for injection to help people with HIV and their healthcare providers more effectively manage comorbidities like lipodystrophy, which today often presents as central adiposity," Chief Medical Officer Christian Marsolais said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 25, 2025 18:16 ET (22:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。